News

Home News
article1

Can Gut Microbes Help More People Benefit from Colorectal Cancer Immunotherapy?

Colorectal cancer, also known as bowel cancer, is a major health concern in Aotearoa New Zealand, with other 3000 people diagnosed annually. Treatments include surgery, chemotherapy, radiotherapy and for some patients immunotherapy. Immunotherapies aim to boost the immune system to recognise and eliminate cancer cells, but their effectiveness is highly variable.

A clinically important feature of CRC is whether the cancer is ‘microsatellite stable’ or ‘microsatellite unstable’. These terms describe changes in the cancer’s DNA. Microsatellite unstable cancers tend to respond better to immunotherapies as they are more likely to induce an immune response. However, 85% of CRC diagnoses are considered microsatellite stable and therefore don’t typically respond well to immunotherapies such as anti-PD-1 therapy.

A recent study used mouse models of microsatellite stable CRC and highlighted that the presence of a gut bacterium Akkermansia muciniphila altered the function of immune cells in CRC and strengthened the response to immunotherapy in mice. Early phase clinical trials on 21 patients with identified tumours shrank in 19% of patients that received a combination of the bacterium and immunotherapy. This is encouraging but much larger studies are required to establish whether the bacterium improves treatment outcomes for patients.

Further research is needed to determine the safety and effectiveness of this approach, but the study opens a promising future avenue for understanding how gut microbes may support immunotherapies in bowel cancer treatment.

For more information on the paper, click the link below: https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(26)00403-8

article1

The Giving Circle Scholarship Award

Applications close 11:59pm, 24th January 2027

The scholarship provides a $2,500 grant to support study-related costs such as tuition, course materials, essential equipment, or specialised tools required for your field of study. 

To apply, the applicant must:

  1. Have a diagnosis of Crohn's disease or ulcerative colitis.
  2. Be accepted into a course of study or training post-high school. 
  3. Be a citizen or resident of New Zealand
  4. Demonstrate how receipt of this award will benefit the community

for more information please email: info@crohnsandcolitis.org.nz

article1

How Gut Bacteria Work Together to Shape Our Health

Our gut is home to trillions of microorganisms that work together to support our health. When this community becomes unbalanced, known as dysbiosis, it has been linked to a range of health conditions, including inflammatory bowel disease and colorectal cancer. A new study published in Science suggests that understanding how gut bacteria interact with one another could provide a clearer picture of gut health than simply measuring which bacteria are present.

Researchers developed a new measure called the ecological network balance index (ENBI), which looks at the balance between positive and negative interactions among gut microbes. Their findings suggest that healthy gut communities tend to have more negative interactions, such as competition between microbes, while disrupted communities show more positive interactions. The measure was able to distinguish between healthy and disrupted gut microbiomes across computer simulations and real-world datasets, and was also associated with disease progression in colorectal cancer.

Although more research is needed before this approach can be used routinely in clinical practice, the findings offer a promising new direction for gut health research. By looking beyond individual bacteria to understand how the whole microbial community functions, researchers hope to develop better ways to identify gut microbiome imbalances, monitor disease progression and eventually tailor treatments to individual patients.

Source: Corral López R, et al. Imbalance in gut microbial interactions as a marker of health and disease. Science, 2026. Read the original study. [Image credit: X. Zhang; edits: A. J. Roldán]

article1

Could a Blood Test Predict Whether an IBD Treatment will Work?

Finding an effective treatment for inflammatory bowel disease (IBD) can involve a lot of trial and error, as there is currently no reliable way to know which patients are most likely to respond to a particular biologic. A recent study by Suarez et al. investigated whether molecules found in the blood could help predict how children with IBD respond to vedolizumab. Vedolizumab is a biologic treatment that helps reduce inflammation by blocking certain immune cells from entering the gut. In children with IBD, it is often used when other treatments have not worked well enough. 

Researchers analysed blood samples from 138 children starting vedolizumab, including 64 with Crohn's disease and 74 with ulcerative colitis. They measured metabolites, which are small molecules in the blood produced as the body carries out its normal processes. The researchers combined these blood measurements with clinical information and used computer-based models to see whether they could predict which children would later go into remission. 

The results were promising. The best model for Crohn's disease reached an AUROC of 0.92, while the best model for ulcerative colitis reached 0.90. An AUROC closer to 1 means the model is better at correctly predicting who will and will not respond to treatment. Several blood metabolites, including citric acid, malic acid, picolinic acid and serotonin, helped the models make these predictions. 

Although more research is needed before this could be used in the clinic, the findings suggest that a blood test could one day help doctors identify which patients are most likely to benefit from vedolizumab. This could make IBD treatment more personalised and reduce the time patients spend trying treatments that may not work for them. 

Article: Suarez RG, Bar Or O, Orlanski-Meyer E, et al. Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study. Inflammatory Bowel Diseases. 2026;32(10):1880-1887. https://doi.org/10.1093/ibd/izag154 

article1

Have You Taken Biologics?

Welcome to this study on the use of biologics for inflammatory bowel disease (IBD).

We are interested in understanding the experiences of patients with IBD who have used infusion or injection biologic medications in the last 6 years. The results of the study may contribute to future proposals for new medications to treat IBD in New Zealand. The study is run through the University of Otago, Department of Medicine, Christchurch. The primary investigator is Professor Richard Gearry and co-investigator Dr Angela Forbes.

This study is for people who have been diagnosed with IBD (Crohn’s disease, ulcerative colitis or inflammatory bowel disease unclassified) who have used one or more, biologic medications since 2020. Examples include: infliximab, adalimumab, vedolizumab, ustekinumab, Remicade, Humira, Amgevita, Entyvio, Stelara. The study should take you around 15 minutes to complete. Participation is voluntary, anonymous, confidential and will not impact your medical care. The study asks about experiences taking biologic medications for IBD, and if the questions raise concerns for you, we encourage you to talk to your GP or contact your IBD nurse. You may withdraw from the study until the final question of the survey has been submitted by contacting Dr Angela Forbes at Angela.Forbes@otago.ac.nz. After the form has been submitted, withdrawal is not possible as responses are anonymous. This study has been approved by the University of Otago Human Ethics Committee (Health), reference H26/0098.

article1

Fasting and Reduced Caloric Intake can Slow Down Tumor Growth in Aged Mice

Researchers from Kumamoto University in Japan investigated whether reducing the caloric intake for mice from 100% to 70% could slow the growth of colorectal tumors. They found that for young mice, there was no suppression of tumor growth in mice fed 70% of their usual dietary requirement. However, in aged mice, there was a marked difference in tumor growth, showing caloric restricted mice had much slower colorectal tumor growth compared to mice fed 100% of their usual dietary calories. They validated their findings in a melanoma model and received the same results, stating the age-dependent tumor suppression was conserved across cancer types. 

They also investigated the mechanism by which tumor growth is slowed down. They stated that the mechanism responsible for this protective effect is enhanced infiltration and activation of CD8+ T cells. These cells are specialised for killing cancer cells and were present at higher numbers in tumors of mice subjected to caloric restriction compared to those on a normal diet, they also had increased expression of markers of cell activation and production of effector molecules. As well as T cell infiltration, they found that the tumors of mice subjected to caloric restriction had more normally structured vasculature. Often in tumors blood vessels become leaky and chaotically arranged, which leads to worse malignancy. Their findings showed that caloric restriction could potentially maintain normal tissue structure and keep tumor tissue functional and non-leaky.  

Altogether this paper shows some promising results, but it is a study conducted solely in mice. Further investigation into the impact of caloric restriction or fasting is warranted within human cancers and could provide some impactful information about how metabolism interacts with cancer. 

Article link: https://www.sciencedirect.com/science/article/pii/S2211124726009228?via%3Dihub

 

 

article1

Giving T Cells a GPS for Colorectal Cancer

Researchers at the University of Colorado are testing a new CAR-T cell therapy for advanced colorectal cancer. CAR-T therapy works by taking a patient’s own T cells and genetically modifying them so they can better recognise and attack cancer cells. You can think of it like giving the immune system a new GPS system that helps T cells find their target. 

In this modern approach, the CAR-T cells are designed to recognise B7-H3, a protein found on many colorectal cancer cells. But the researchers are also targeting IL-8, a molecule in the tumour environment that can help cancer grow and make it harder for immune cells to work effectively. By attacking both the cancer cells and the environment that helps protect them, researchers hope to give CAR-T cells a better chance of fighting colorectal cancer. 

Article: https://www.eurekalert.org/news-releases/1143707  

Photo Source: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells  

 

article1

Could AI be your new doctor? Researchers say: “probably not”

Due to the ever-increasing use of large language models like ChatGPT for health consultation, the need for digital literacy is at an all-time high. However, we still have little understanding of the true accuracy of the responses generated by these models. Further, even if the information given is accurate, the ability for individuals to understand the responses is critical, particularly when they pertain to health and nutrition.

 A study by Khademi et al. aimed to explore the scientific accuracy and readability of ChatGPT responses to nutritional queries related to inflammatory bowel disease (IBD). Researchers gathered twenty frequently asked questions from Google and posed them in independent sessions to ChatGPT version 3.5. The questions varied in complexity, ranging from “Can I eat rice with Crohn’s?”, to “What nutritional deficiencies are common in inflammatory bowel disease?”. The responses to these questions were then assessed by nutritionists and dietitians specialising in IBD.

 The researchers found that overall, responses to these queries were rated 4.2/5 for scientific accuracy, and 4.3/5 for comprehensibility by the the IBD specialists. In terms of readability, responses required an average of about 13 years of education to be understood, though this was highly dependent on the specific question being asked.

 Though the responses may have been difficult to read, these findings suggest that for general nutritional queries, ChatGPT may be a source of relatively accurate and comprehensible information for patients with IBD. However, accuracy and readability decreased for more complex queries, so further research is needed to validate these findings and explore more specialised nutrition topics.

 To see all the questions that were asked and for a breakdown of the accuracy, comprehensibility, and readability of each query, see the full article here: https://doi.org/10.1038/s41598-026-66091-2

article1

Phase 1 Trial of Faecalibacterium prausnitzii Supports Microbiome Based Therapy in Crohn’s Disease

A new study published in Nature Communications reports the first human clinical evaluation of Faecalibacterium prausnitzii as a live biotherapeutic for Crohn’s Disease. F. prausnitzii is a dominant commensal bacterium in the healthy gut microbiome and is widely recognized for its anti-inflammatory and immunomodulatory properties. Reduced abundance of this organism has been consistently associated with intestinal inflammation, disease severity, and relapse risk in Crohn’s disease. In this Phase 1 trial, patients with mild to moderate Crohn’s disease received an oral formulation of a proprietary F. prausnitzii strain (EXL01), with the primary aim of assessing safety and tolerability.

The therapy was found to be safe and biologically active, with no major treatment-related adverse events reported. Importantly, molecular analyses revealed that treatment was associated with changes in ileal gene expression, including reduced activation of inflammatory and innate immune pathways and enhancement of metabolic pathways linked to epithelial homeostasis. These findings suggest that F. prausnitzii may exert therapeutic effects through modulation of host immune responses and restoration of intestinal epithelial function. Although the study was limited by small sample size and lack of a placebo control, it provides important proof-of-concept evidence supporting microbiome-targeted therapeutics as a novel treatment strategy for Crohn’s disease.

ClinicalTrials.gov registration: NCT05542355.

Guarino-Vignon, P., Louis, E., Pham, HP. et al. Faecalibacterium prausnitzii EXL01 for the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Crohn’s Disease: a first in human trial. Nat Commun (2026). https://doi.org/10.1038/s41467-026-72375-y

article1

Early Clues to Parkinson’s Disease Found in the Gut

Researchers have identified changes in gut bacteria that may signal the earliest stages of Parkinson’s disease in people who carry a genetic risk factor linked to the condition.

In a study published in Nature Medicine, scientists analysed stool samples and clinical data from people with Parkinson’s disease, healthy individuals, and symptom-free carriers of a variant of the GBA1 gene, which increases the risk of developing the disease.

The team found that more than a quarter of gut microbial species differed between healthy people and those with Parkinson’s disease. Strikingly, many of the same bacterial changes were also present in GBA1 carriers who had not yet developed symptoms. Their gut microbiomes appeared to sit midway between those of healthy individuals and people with Parkinson’s disease, and the extent of these changes was linked to subtle early symptoms.

Parkinson’s disease is usually diagnosed only after significant loss of brain cells has occurred. The discovery that gut microbiome changes may appear before noticeable symptoms raises the possibility of identifying people at higher risk earlier.

However, the researchers caution that the study cannot show whether these microbial changes predict future disease. Long-term studies are needed to determine their role in Parkinson’s development.

Original article: Menozzi, E., Ren, Y., Geiger, M. et al. Microbiome signature of Parkinson’s disease in healthy and genetically at-risk individuals. Nat Med (2026). https://doi.org/10.1038/s41591-026-04318-5

1 2 3 4 5 ... 12